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Abstract 34 
Bacteriocins are ribosomally synthesized peptides produced by bacteria which can kill other 35 
bacteria. Those produced by lactic acid bacteria (LAB) are of great interest as they are often 36 
employed in food processing and food fermentations as natural biopreservatives. In this 37 
review, we discuss the implementation of bioengineering to enhance the antimicrobial 38 
activity, antibacterial spectrum and physico-chemical properties of LAB bacteriocins. 39 
Additionally, we discuss the potential applications of bacteriocin derivatives for use as 40 
promising food preservatives alone or in combination with other naturally derived 41 
antimicrobials as a form of hurdle technology and the regulatory status of strains engineered 42 
through food-grade approaches.   43 
 44 
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Highlights 58 
 59 
• Bioengineering can generate novel bacteriocin variants for specific purposes.  60 
 61 
• Genome mining has identified new bacteriocin biosynthetic gene clusters.  62 
  63 
• Bioengineered bateriocins show great promise as synergists in hurdle technology.  64 
 65 
• Bacteriocin producing strains which have been tailored through food-grade methods 66 
can be directly added to food. 67 
 68 
 69 
Introduction 70 
 71 
The growth in world population and the globalization of food commerce has led to large scale 72 
food production practices requiring ever longer transport networks and extended storage 73 
times until final distribution to consumers.  In addition, growing consumer demand for food 74 
products that are minimally processed and free from chemical additives presents a 75 
complicated and difficult challenge for food processors. Such demand has opened up new 76 
opportunities for the use of natural antimicrobials derived from plant, animal or microbial 77 
sources to control the growth of undesirable micro-organisms in food [1,2].  Bacteriocins 78 
(ribosomally-produced, small, heat-stable peptides that are active against other bacteria) 79 
provide one potential solution. While bacteriocins can be produced by a range of Gram-80 
positive and Gram-negative bacteria [3], those produced by lactic acid bacteria (LAB) are of 81 
particular interest to the food industry for several reasons. Firstly, members of the LAB group 82 
have a history of safe use as starter cultures in food fermentations and many possess 83 
“Generally Regarded as Safe (GRAS)” status according to the US Food and Drug 84 
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Administration [4]. Secondly, besides being non-toxic to eukaryotic cells, LAB bacteriocins 85 
are extremely potent against many food spoilage microbes and pathogenic bacteria, 86 
demonstrating killing activity in the nanomolar range.  Thirdly, they do not interfere with the 87 
sensory quality of foods. Finally, the ribosomal origin of bacteriocins has enabled the 88 
manipulation of the associated structural gene in a more direct fashion than is possible for 89 
other classes of antimicrobials to obtain variants with potentially beneficial properties. 90 
Indeed, several groups have reported on the enhancement of bacteriocins’ performance in 91 
food environments, including the engineering of derivatives with enhanced activity and 92 
inhibition spectra, increased resistance to proteolytic enzymes as well as the combination of 93 
such derivatives with other natural antimicrobials in the form of hurdle technology. This 94 
review will focus on recent developments with regard to these achievements and present the 95 
latest innovations which aim to harness the full potential of these highly potent 96 
antimicrobials. 97 
Classification of LAB Bacteriocins  98 
Bacteriocins produced by LAB represent a heterogeneous group of peptides encoded by a 99 
diverse genetic repertoire. Some are post-translationally modified and this aspect, together 100 
with their mode of action, has traditionally been used as a basis for their classification [5]. 101 
The simplest scheme comprises two classes; i.e. Class I bacteriocins also known as RiPPs 102 
(Ribosomally Produced and Post-translationally modified Peptides) encompasses all the 103 
peptides that undergo enzymatic modification during their biosynthesis (including 104 
lanthionines, glycosylation and/or heterocycles). Class II do not contain unusual 105 
modifications. However, recent extensive genome mining analysis of LAB suggests that the 106 
repertoire of antimicrobials that are encoded in publicly available sequence databases could 107 
be even more extensive than previously thought, with some putative classes thus far not 108 
reported in LAB (e.g. lasso peptides and sactipeptides) [6]. Furthermore, an in silico 109 
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screening approach of genome-sequenced isolates from the human gastrointestinal tract (GIT) 110 
identified more than 70 clusters of note from almost 60 unique members including 111 
Firmicutes, Bacteroidetes, Actinobacteria, and others [7]. The most commonly identified 112 
class of bacteriocin was the >10 kDa class, formerly known as bacteriolysins, followed by 113 
lantibiotics and sactipeptides [7]. Consequently, a revised scheme (that is also valid for 114 
bacteriocins from non-LAB micro-organisms) proposes three classes in which Class I is 115 
divided into six subclasses representing different modifications, Class II comprises four 116 
subclasses of unmodified peptides of <10kDa and Class III are large-molecular-weight 117 
(>10kDa) proteins and are subdivided into the bacteriolysins and the non-lytic bacteriocins 118 
[6]. 119 
Bioengineering to modulate the physicochemical properties of LAB bacteriocins 120 
Despite the amount of research that has been carried out on the discovery, characterization 121 
and mode of action of LAB bacteriocins over the last few decades, to date, just a handful 122 
have been commercialized to any extent. These include nisin, a lantibiotic peptide produced 123 
by Lactococcus lactis [8], pediocin PA-1 produced by Pediococcus acidilactici [9] and 124 
carnocyclin A produced by Carnobacterium maltaromaticum UAL307 [10]. However, 125 
studies with other LAB bacteriocins including enterocin AS-48 [11] or lacticin 3147 [12] 126 
demonstrate their enormous potential as biopreservatives in food. Nisin is used in most major 127 
food-producer countries as a concentrated fermentate powder (e.g. Nisaplin) in a wide variety 128 
of dairy and non-dairy products to control the growth of Gram positive bacteria [13]. A 129 
fermentate powder produced from the pediocin-producing strain Pediococcus acidilactici 130 
(ALTA 2351, Kerry Biosciences, Ireland) can be used to protect meat products from L. 131 
monocytogenes contamination [14]. Carnocyclin A is marketed as Micocin in the US and 132 
Canada and has been developed to inhibit Listeria monocytogenes in ready-to-eat meat (RTE) 133 
products [10]. Accordingly, these bacteriocins have been the subject of several 134 
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bioengineering strategies (For comprehensive reviews see [15-17]) that have sought to 135 
improve bacteriocin efficacy in the food environment. Peptide function can be influenced by 136 
a number of factors including fat content, proteolytic degradation, polar or non-polar food 137 
components, pH (which influences the solubility of the bacteriocin) and sodium chloride 138 
concentrations [18]. For example, the limited activity spectrum of nisin with respect to pH 139 
and its intrinsic insolubility has emphasized the need for alternative versions that exhibit 140 
superior stability and are suitable for food fermentation and preservation practices. The 141 
natural variant nisin Z, which differs from nisin A by one amino acid (asparagine rather than 142 
histidine at position 27) provides an example of a derivative with improved functional 143 
characteristics since, while it has similar antimicrobial activity to nisin A, nisin Z displays a 144 
higher rate of diffusion [19] and is less soluble at low pH [20]. Recently, bioengineered nisin 145 
derivatives were identified with an enhanced ability to diffuse through complex polymers that 146 
enabled the peptides to surpass nisin A in restricting growth of Listeria monocytogenes in 147 
commercially produced chocolate milk containing carrageenan as a stabilizer [21]. Despite 148 
the fact that derivatives of the unmodified class II bacteriocins can be generated with relative 149 
ease [22], there are comparatively few examples of instances in which LAB producers of the 150 
class II bacteriocins have been engineered to positive effect. However, in the case of pediocin 151 
PA-1/AcH, greater resistance to oxidation was achieved by the replacement of a methionine 152 
moiety with a hydrophobic one, which had only minor effects on antimicrobial activity [23]. 153 
Such modifications are an important step in the development of pediocin PA-1 into an 154 
advantageous food additive. Some studies have aimed to incorporate protease resistance into 155 
LAB-derived peptides. For example, particular modification of trypsin recognition sites in the 156 
class IIb bacteriocin salivaricin P produced by Lactobacillus salivarius had only minor 157 
effects on activity [24]. 158 
 159 
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Bioengineering to modulate the antimicrobial activity and spectrum of LAB 160 
bacteriocins 161 
The range of inhibitory activity by LAB bacteriocins can be either narrow, inhibiting only 162 
those strains that are closely related to the producer organism, or wide, inhibiting a broad 163 
range of Gram-positive micro-organisms [25]. Several investigations have sought to identify 164 
nisin derivatives that are enhanced with respect to the purpose for which nisin is most 165 
renowned, the inhibition of Gram-positive bacteria [15]. One remarkable derivative, nisin A 166 
M21V (Nisin V) (Fig. 1) exhibits enhanced potency against a wide range of targets, most 167 
notably L. monocytogenes. Furthermore, this enhanced activity was apparent in food model 168 
experiments with purified peptide [26]. L. monocytogenes is of major concern to the food 169 
industry. Apart from the risk to human health, food product recalls due to Listeria 170 
contamination present an enormous financial burden, estimated to be in the billions of dollars 171 
per year in the United States [27].  Recently, nisin V in the form of a fermentate, combined 172 
more effectively than nisin A with the essential oils carvacrol, thymol and trans-173 
cinnamaldehyde to inhibit L. monocytogenes in a validated food model system [28]. 174 
Worryingly, L. monocytogenes has the ability to form biofilms providing it with the means to 175 
survive on contact surfaces, with higher levels of resistance to disinfectants and potential for 176 
growth under the rigorous conditions used for food processing. This could lead to 177 
contamination of food products. A recent study demonstrated the effectiveness of nisin 178 
M21A, in combination with natural food-grade additives, in targeting biofilms of L. 179 
monocytogenes F6854 [29], a strain that has been associated with contaminated turkey 180 
frankfurters. Similarly, the advantage of shortening or extending the hinge region of nisin has 181 
generated variants with improved bioactivity against one or more indicator targets, including 182 
L. monocytogenes, E. faecalis and B. sporothermodurans [30]. Bioengineering to enhance the 183 
efficacy of Class IIa bacteriocins has also been considered. Mutated peptides in which 184 
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residues were substituted within the N-terminal half of pediocin PA-1 exhibited increased 185 
activity against Micrococcus luteus and Staphylococcus aureus [31], while variants within the 186 
C-terminus displayed increased potency towards L. monocytogenes [32]. Directed 187 
mutagenesis studies have been employed to manipulate enterocin AS-48, a broad-spectrum 188 
circular bacteriocin produced by a strain of E. faecalis [33]. The authors determined that 189 
enterocin AS-48 was active in a dimeric form, and established the essential residues involved 190 
in these interactions [34]. Such knowledge may facilitate the design and expression of novel 191 
variants with improved antimicrobial activity. Notably, the successful chemical synthesis of 192 
circular bacteriocins including enterocin AS-48 has recently been achieved [35], providing a 193 
more suitable means to generate novel variants, the production of which can often be 194 
compromised in the native producer.  195 
The poor activity of LAB bacteriocins toward Gram negative bacteria is due to the outer 196 
membrane (OM) of the Gram negative cell wall [36]. The OM functions as an efficient 197 
permeability barrier and is able to exclude macromolecules such as bacteriocins or enzymes. 198 
Importantly, bioengineered nisin variants S29A and S29G have been shown to display 199 
improved activity against Gram negative bacteria [37]. Moreover, while nisin A has been 200 
shown to be effective against Gram negatives when used in combination with chelating 201 
agents such as EDTA [38], perhaps a more attractive option for food applications is the 202 
combination of nisin with natural phytochemical compounds such as essential oils, which act 203 
by permeabilization/disruption of the OM. [39]. Recent investigations have also sought to 204 
extend the antimicrobial spectrum of pediocin-like bacteriocins to include Gram-negative 205 
bacteria. The enterocin CRL35, a pediocin-like bacteriocin, has a potent antilisterial activity 206 
but is inactive against Gram-negative targets. In contrast, microcin V (previously known as 207 
colicin V) is specifically active against Gram-negative bacteria [40]. A hybrid bacteriocin 208 
named Ent35–MccV resulting from the gene fusion of the enterocin CRL35 and microcin V 209 
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genes (munA and cvaC, respectively) displayed inhibitory activity against E. coli, L. 210 
monocytogenes, and other pathogenic Gram-positive and Gram-negative bacteria [41]. 211 
Synthetic biology approaches are another promising means to provide insights into structure-212 
stability relationships and generate novel derivatives with improved function. For example, 213 
analogues of Lacticin 481 containing non-proteinogenic amino acids were found to have 214 
enhanced antibacterial activity [42]. 215 
 216 
 217 
 
218 
 219 
Heterologous expression to increase yield and multiple bacteriocin production 220 
  221 
One of the issues that remains to be tackled is that of bacteriocin production, which can be 222 
low or inconsistent in lactic acid bacteria and which can be affected by poor growth of 223 
producing strains in particular food environments. Although the heterologous production of 224 
bacteriocins by LAB is reliant on several factors, bioengineering techniques can facilitate 225 
increased levels of bacteriocin production. Some efforts to increase bacteriocin yield have 226 
involved using synthetic genes encoding bacteriocins cloned and expressed in yeasts. For 227 
instance, the use of codon optimization was recently employed to overcome the bottleneck of 228 
low yield of Enterocin A, a class IIa bacteriocin produced by Enterococcus faecium CTC492 229 
[43]. Likewise, a recent study involving synthetic biology approaches describes the 230 
development of a genetic system that facilitates significant overproduction of nisin [44]. Such 231 
innovative systems could potentially reduce the cost of bacteriocin production and also 232 
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provides a means by which sufficient quantities of bacteriocin can be produced in situ.  In 233 
addition, novel bacteriocin clusters identified through genome mining and considered highly 234 
advantageous to the food industry could be cloned and expressed in suitable hosts. In fact, 235 
bacteriocin producing bioprotective cultures that target particular pathogens are commercially 236 
available under various trade names [45]. Remarkably, naturally occurring multi-bacteriocin 237 
producing LAB have been reported [46]. Consequently, the use of bacteriocin combinations 238 
or bacteriocin ‘loading’ may represent a useful approach whereby an assortment of 239 
bacteriocins produced in situ provide an effective cocktail that can act synergistically to 240 
inhibit desired target pathogens.  Indeed, some optimistic reports are emerging on the use of 241 
multi-bacteriocin mixtures for the effective control of foodborne pathogens such as Listeria 242 
[47,48].  243 
 244 
Bioengineering and the Regulation of Genetically Modified Micro-organisms 245 
Although the application of bioengineering has been instrumental in the fundamental 246 
analyses of bacteriocin biology, mode of action studies, and the ability to design more potent 247 
peptides with enhanced properties and target selectivity, the application of such peptides as 248 
food preservatives may face a significant regulatory obstacle in some jurisdictions. The 249 
genetic manipulation of bacteriocins or the producer strains needs to pass through strict safety 250 
regulations and guidelines laid down by regulatory agencies such as the FDA (or the 251 
European Food Safety Authority [EFSA] in Europe) for approval to be used in human 252 
consumption. Indeed, some of the strategies employed to bioengineer many of the 253 
bacteriocins described above involve methods that could result in the producer being labelled 254 
as a genetically modified micro-organism (GMM). Alternatively, self-cloning of non-255 
pathogenic micro-organisms is not considered to lead to a GMM so long as containment of 256 
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the organism is guaranteed (directive 90/219/EC). Notably, the temporary introduction of 257 
plasmid vectors or the use of recombinant vectors with an extended history of safe use in the 258 
particular micro-organisms, or introduction of DNA from another micro-organism belonging 259 
to the same species fall within the definition of self-cloning. Thus, minimal changes to 260 
bacteriocin structural genes (such as the alteration of single codons) made using food grade 261 
strategies [26,49] fall outside the remit of the EFSA Contained Use legislation and therefore 262 
are not regulated as GMMs.  263 
 264 
 
265 
 266 
Conclusions 267 
A broad range of technologies have emerged in recent years that provide a battery of valuable 268 
tools to expand the potential of bacteriocinogenic strains for food applications. The 269 
knowledge gained will improve our understanding on the global effects of bacteriocins in 270 
food ecosystems and permit more rational approaches for their application in foods. Several 271 
bioengineered bacteriocins capable of inhibiting food-associated Gram positive and Gram-272 
negative bacteria of concern have been recently described. A number have already been 273 
tested with satisfactory results in terms of the control of pathogenic bacteria in model food 274 
systems. Moreover, their use in combination with other naturally derived antimicrobials in 275 
the form of hurdle technology may open new possibilities for the control of a broad range of 276 
undesirable organisms. Although genetic manipulation by recombinant and bioengineering-277 
based approaches hold great promise, only bacteriocins which have been tailored through 278 
food-grade methodologies can be directly added to food. Furthermore, as the number of 279 
microbial genome sequences has increased exponentially, an even larger collection of 280 
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putative bacteriocin biosynthetic gene clusters has been revealed. These clusters can be used 281 
to identify producer strains, or the information gained from their analysis can be used 282 
indirectly to guide the bioengineering of new and existing peptide structures with enhanced 283 
functionality for use in the food industry. 284 
 285 
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Figure 1. Bioengineering bacteriocins: bacteriocins with improved physicochemical 446 
properties (pH, solubility) have been generated as well as novel variants with improved 447 
activity, target spectrum and anti-biofilm efficacy. Bioengineered variants can act 448 
synergistically to inhibit desired target pathogens in the form of hurdle technology. Genome 449 
mining has identified an even larger collection of new bacteriocin biosynthetic gene clusters 450 
which can be used to guide the bioengineering of new and existing peptide structures. 451 
Bioengineered strains which have been tailored through food-grade approaches are not 452 
considered GMMs and can be directly added to food. 453 
 454 
